Idorsia UK, an affiliate of Idorsia Ltd, is reaching out for more – We have more ideas, we see more opportunities and we want to help more patients. To achieve this, we will develop Idorsia into a leading biopharmaceutical company, with a strong scientific core.
With commercial operations based in London, we are helping to realize the company’s ambition of bringing innovative medicines from bench to bedside.

Our goal is to build a commercial footprint that will deliver Idorsia’s deep pipeline of products from its R&D engine to the UK market – with the potential to change the lives of many patients.

Headquartered in Switzerland, Idorsia Ltd was listed on the SIX Swiss Exchange (ticker symbol: IDIA) in June 2017 and has over 800 highly qualified specialists dedicated to realizing our ambitious targets.


We have identified five key strategic priorities to ensure the company’s success over the first five years.


Idorsia’s corporate responsibility efforts encompass employee development and diversity, governance and ethics, as well as the organization’s economic, environmental, and social performance.


It’s the Idorsia team’s passion for science that will translate our objectives into value creation for all our stakeholders.

Research & Development

Idorsia aims to deliver new products with the potential to significantly change the treatment options in their target diseases.